Stock Events

Stock Events

Alnylam Pharmaceuticals 

€141.20
211
-€8.00-5.36%Friday 16:32

Statistics

Day High
141.2
Day Low
141.2
52W High
225.9
52W Low
140.95
Volume
0
Avg. Volume
23
Mkt Cap
18.91B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Oct 29Expected
Q2 2026
Q3 2026
1.05
5.39
9.72
14.06
Expected EPS
1.4841416180600002
Actual EPS
14.0577672

Financials

8.22%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
3.2BRevenue
263.44MNet Income

Analyst Ratings

$241.30Average Price Target
The highest estimate is ⁦345.25⁩.
From 21 ratings within the last 6 months. This is not an investment recommendation.
Buy
76%
Hold
24%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALNY.VI. It's not an investment recommendation.
NVIDIA
52
NVDA
Microsoft
47
MSFT
Apple
45
AAPL
Amazon
45
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Ionis Pharmaceuticals
IONS
Mkt Cap7.23B
Ionis Pharmaceuticals competes directly with Alnylam in the development of RNA-targeted therapies.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap8.46B
Arrowhead Pharmaceuticals is a direct competitor in RNA interference (RNAi) therapeutics, similar to Alnylam's core technology.
Moderna
MRNA
Mkt Cap88.52B
Moderna, Inc. competes in the broader RNA space with its mRNA technology, which can be seen as complementary or competitive to Alnylam's RNAi.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical competes with Alnylam in the rare disease space, particularly in treatments that could overlap with Alnylam's patient populations.
Sarepta Therapeutics
SRPT
Mkt Cap1.97B
Sarepta Therapeutics, focusing on RNA-based therapies, particularly for rare diseases, competes for similar patient populations and therapeutic areas as Alnylam.
Novartis
NVS
Mkt Cap303.67B
Novartis AG has a broad interest in RNA-based therapies and has been involved in collaborations and competition in the RNA space, including areas Alnylam is targeting.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. has a diverse portfolio that includes investments in RNA therapies and rare diseases, making it a competitor on multiple fronts.

About

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Show More
CEO
Yvonne L. Greenstreet
Employees
2500
Country
United States
ISIN
US02043Q1076
WKN
000A0CBCK

Listings

MI
IT
1ALNY.MI
STU
DE
DUL.STU
XETRA
DE
DUL.XETRA
MX
MX
ALNY.MX

0 Comments

Share your thoughts

FAQs

What is Alnylam Pharmaceuticals stock price today?▼
The current price of ALNY.VI is €141.20 EUR — it has decreased by -5.36% in the past 24 hours. Watch Alnylam Pharmaceuticals stock price performance more closely on the chart.
What is Alnylam Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Vienna Exchange exchange Alnylam Pharmaceuticals stocks are traded under the ticker ALNY.VI.
What is Alnylam Pharmaceuticals market cap?▼
Today Alnylam Pharmaceuticals has the market capitalization of 18.91B
When is the next Alnylam Pharmaceuticals earnings date?▼
Alnylam Pharmaceuticals is going to release the next earnings report on February 18, 2027.
What were Alnylam Pharmaceuticals earnings last quarter?▼
ALNY.VI earnings for the last quarter are 14.06 EUR per share, whereas the estimation was 1.48 EUR resulting in a +847.2% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Alnylam Pharmaceuticals revenue for the last year?▼
Alnylam Pharmaceuticals revenue for the last year amounts to 3.2B EUR.
What is Alnylam Pharmaceuticals net income for the last year?▼
ALNY.VI net income for the last year is 263.44M EUR.
How many employees does Alnylam Pharmaceuticals have?▼
As of November 8, 2026, the company has 2,500 employees.
In which sector is Alnylam Pharmaceuticals located?▼
Alnylam Pharmaceuticals operates in the Health & Wellness sector.
When did Alnylam Pharmaceuticals complete a stock split?▼
Alnylam Pharmaceuticals has not had any recent stock splits.
Where is Alnylam Pharmaceuticals headquartered?▼
Alnylam Pharmaceuticals is headquartered in CAMBRIDGE, United States.